(NVO) Novo Nordisk - Ratings and Ratios
Insulin, Obesity Medication, Hemophilia Drugs, Growth Hormone, Diabetes Pens
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 38.6% |
| Value at Risk 5%th | 57.0% |
| Relative Tail Risk | -10.36% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.26 |
| Alpha | -64.23 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.620 |
| Beta | 0.764 |
| Beta Downside | 0.824 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.50% |
| Mean DD | 20.54% |
| Median DD | 7.72% |
Description: NVO Novo Nordisk September 24, 2025
Novo Nordisk A/S (NYSE:NVO) is a Denmark-based, globally-distributed pharmaceutical company that develops, manufactures, and markets medicines across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America and other regions.
The firm operates two primary segments: (1) Diabetes & Obesity Care, which supplies insulin, GLP-1 agonists, and emerging cardiovascular and obesity therapies; and (2) Rare Disease, which focuses on treatments for rare blood and endocrine disorders as well as hormone-replacement products. Ancillary offerings include insulin and growth-hormone pens, injection needles, and digital tools such as smart insulin pens and the Dose Check dose-guidance app.
Strategic collaborations augment its pipeline: a UNICEF partnership targets childhood obesity, while a joint venture with Valo Health aims to discover novel cardiometabolic candidates. Novo Nordisk was founded in 1923 and remains headquartered in Bagsværd, Denmark.
Key recent metrics (FY 2023): revenue of DKK 141 billion (≈ US$ 20 billion), a 12 % YoY increase driven largely by growth in GLP-1 products; R&D spend of DKK 15 billion (≈ 2 % of sales), reflecting continued investment in next-generation obesity and rare-disease pipelines; and an operating margin of 31 %, well above the GICS Pharmaceuticals average of 22 %. The diabetes market’s secular tailwinds-rising global prevalence (≈ 537 million adults) and expanding indications for GLP-1 agents-support Novo Nordisk’s revenue outlook, while pricing pressure in mature insulin markets remains a risk factor.
For a deeper quantitative assessment of Novo Nordisk’s valuation metrics, the ValueRay platform offers a granular, data-driven view worth exploring.
NVO Stock Overview
| Market Cap in USD | 221,332m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1982-01-04 |
| Return 12m vs S&P 500 | -56.9% |
| Analyst Rating | 3.50 of 5 |
NVO Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 3.54% |
| Yield on Cost 5y | 5.42% |
| Yield CAGR 5y | 21.92% |
| Payout Consistency | 96.1% |
| Payout Ratio | 7.2% |
NVO Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -4.68% |
| CAGR/Max DD Calmar Ratio | -0.07 |
| CAGR/Mean DD Pain Ratio | -0.23 |
| Current Volume | 16253.7k |
| Average Volume | 14406.5k |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (103.77b TTM) > 0 and > 6% of Revenue (6% = 18.94b TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA -4.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -16.63% (prev -4.88%; Δ -11.75pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.24 (>3.0%) and CFO 123.78b > Net Income 103.77b (YES >=105%, WARN >=100%) |
| Net Debt (69.13b) to EBITDA (163.70b) ratio: 0.42 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.45b) change vs 12m ago -0.31% (target <= -2.0% for YES) |
| Gross Margin 82.05% (prev 84.66%; Δ -2.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 69.38% (prev 68.08%; Δ 1.30pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.15 (EBITDA TTM 163.70b / Interest Expense TTM 17.96b) >= 6 (WARN >= 3) |
Altman Z'' 3.08
| (A) -0.10 = (Total Current Assets 181.88b - Total Current Liabilities 234.36b) / Total Assets 512.29b |
| (B) 0.33 = Retained Earnings (Balance) 168.53b / Total Assets 512.29b |
| (C) 0.32 = EBIT TTM 146.44b / Avg Total Assets 454.86b |
| (D) 0.50 = Book Value of Equity 169.90b / Total Liabilities 342.39b |
| Total Rating: 3.08 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 89.06
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 4.20% = 2.10 |
| 3. FCF Margin 19.88% = 4.97 |
| 4. Debt/Equity 0.60 = 2.33 |
| 5. Debt/Ebitda 0.42 = 2.36 |
| 6. ROIC - WACC (= 35.86)% = 12.50 |
| 7. RoE 66.95% = 2.50 |
| 8. Rev. Trend 92.37% = 6.93 |
| 9. EPS Trend 87.53% = 4.38 |
What is the price of NVO shares?
Over the past week, the price has changed by -3.26%, over one month by -14.69%, over three months by -11.53% and over the past year by -51.05%.
Is NVO a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the NVO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 57.2 | 20.3% |
| Analysts Target Price | 57.2 | 20.3% |
| ValueRay Target Price | 40.7 | -14.5% |
NVO Fundamental Data Overview November 15, 2025
P/E Trailing = 13.5801
P/E Forward = 12.4844
P/S = 0.7013
P/B = 8.4726
P/EG = 1.6027
Beta = 0.352
Revenue TTM = 315.60b DKK
EBIT TTM = 146.44b DKK
EBITDA TTM = 163.70b DKK
Long Term Debt = 89.18b DKK (from longTermDebt, last quarter)
Short Term Debt = 12.03b DKK (from shortTermDebt, last quarter)
Debt = 101.21b DKK (from shortLongTermDebtTotal, last quarter)
Net Debt = 69.13b DKK (from netDebt column, last quarter)
Enterprise Value = 1494.87b DKK (1426.24b + Debt 101.21b - CCE 32.58b)
Interest Coverage Ratio = 8.15 (Ebit TTM 146.44b / Interest Expense TTM 17.96b)
FCF Yield = 4.20% (FCF TTM 62.74b / Enterprise Value 1494.87b)
FCF Margin = 19.88% (FCF TTM 62.74b / Revenue TTM 315.60b)
Net Margin = 32.88% (Net Income TTM 103.77b / Revenue TTM 315.60b)
Gross Margin = 82.05% ((Revenue TTM 315.60b - Cost of Revenue TTM 56.66b) / Revenue TTM)
Gross Margin QoQ = 76.12% (prev 83.29%)
Tobins Q-Ratio = 2.92 (Enterprise Value 1494.87b / Total Assets 512.29b)
Interest Expense / Debt = 4.95% (Interest Expense 5.01b / Debt 101.21b)
Taxrate = 21.60% (5.51b / 25.52b)
NOPAT = 114.81b (EBIT 146.44b * (1 - 21.60%))
Current Ratio = 0.78 (Total Current Assets 181.88b / Total Current Liabilities 234.36b)
Debt / Equity = 0.60 (Debt 101.21b / totalStockholderEquity, last quarter 169.90b)
Debt / EBITDA = 0.42 (Net Debt 69.13b / EBITDA 163.70b)
Debt / FCF = 1.10 (Net Debt 69.13b / FCF TTM 62.74b)
Total Stockholder Equity = 155.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.26% (Net Income 103.77b / Total Assets 512.29b)
RoE = 66.95% (Net Income TTM 103.77b / Total Stockholder Equity 155.00b)
RoCE = 59.97% (EBIT 146.44b / Capital Employed (Equity 155.00b + L.T.Debt 89.18b))
RoIC = 44.36% (NOPAT 114.81b / Invested Capital 258.80b)
WACC = 8.50% (E(1426.24b)/V(1527.45b) * Re(8.83%) + D(101.21b)/V(1527.45b) * Rd(4.95%) * (1-Tc(0.22)))
Discount Rate = 8.83% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.34%
[DCF Debug] Terminal Value 76.14% ; FCFE base≈64.61b ; Y1≈67.41b ; Y5≈77.85b
Fair Price DCF = 351.3 (DCF Value 1183.34b / Shares Outstanding 3.37b; 5y FCF grow 4.61% → 3.0% )
EPS Correlation: 87.53 | EPS CAGR: 139.0% | SUE: 1.50 | # QB: 1
Revenue Correlation: 92.37 | Revenue CAGR: 17.52% | SUE: -0.03 | # QB: 0
Additional Sources for NVO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle